RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)